1. Home
  2. CDXS vs SGMO Comparison

CDXS vs SGMO Comparison

Compare CDXS & SGMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Codexis Inc.

CDXS

Codexis Inc.

HOLD

Current Price

$1.65

Market Cap

141.8M

Sector

Industrials

ML Signal

HOLD

Logo Sangamo Therapeutics Inc.

SGMO

Sangamo Therapeutics Inc.

HOLD

Current Price

$0.41

Market Cap

155.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CDXS
SGMO
Founded
2002
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
141.8M
155.1M
IPO Year
2010
2000

Fundamental Metrics

Financial Performance
Metric
CDXS
SGMO
Price
$1.65
$0.41
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$4.71
AVG Volume (30 Days)
1.0M
5.5M
Earning Date
11-06-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$52,932,000.00
$32,875,000.00
Revenue This Year
$15.64
N/A
Revenue Next Year
$5.23
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.52
$0.38
52 Week High
$5.51
$2.73

Technical Indicators

Market Signals
Indicator
CDXS
SGMO
Relative Strength Index (RSI) 42.19 37.31
Support Level $1.62 $0.43
Resistance Level $1.75 $0.49
Average True Range (ATR) 0.08 0.02
MACD 0.01 -0.00
Stochastic Oscillator 11.43 0.65

Price Performance

Historical Comparison
CDXS
SGMO

About CDXS Codexis Inc.

Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.

About SGMO Sangamo Therapeutics Inc.

Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.

Share on Social Networks: